A research team develops a new monoclonal antibody checkpoint inhibitor for advanced melanoma that has shown promise in animal studies as well as high efficacy and low toxicity in early phase human clinical trials. The research team would now like to compare this drug to existing standard of care immunotherapy for advanced melanoma. The research team decides to conduct a non-randomized study where the novel drug will be offered to patients who are deemed to be at risk for toxicity with the current standard of care immunotherapy, while patients without such risk factors will receive the standard treatment. Which of the following best describes the level of evidence that this study can offer?
ALevel 1
BLevel 3
CLevel 5
DLevel 4
ELevel 2
A 61-year-old woman is brought to the emergency department because of fever, chills, and flank pain for 8 hours. Her temperature is 39.1°C (102.4°F). Physical examination shows right costovertebral angle tenderness. Urine dipstick is positive for nitrites. Urinalysis shows gram-negative rods. The patient is admitted to the hospital and treatment with a drug that directly inhibits bacterial DNA replication is begun. This drug inhibits a protein that is normally responsible for which of the following steps of DNA replication?
AExcising RNA fragments in 5' to 3' direction
BCleaving DNA to relieve supercoils
CBinding to single-stranded DNA to prevent reannealing
DUnwinding DNA at replication fork
EJoining of short DNA fragments
A 71-year-old man with colorectal cancer comes to the physician for follow-up examination after undergoing a sigmoid colectomy. The physician recommends adjuvant chemotherapy with an agent that results in single-stranded DNA breaks. This chemotherapeutic agent most likely has an effect on which of the following enzymes?
ADNA polymerase III
BTopoisomerase I
CHelicase
DTelomerase
ETopoisomerase II
+ 7 more in the PDF
Browse all chapters